UY39517A - Inhibidores de la btk - Google Patents

Inhibidores de la btk

Info

Publication number
UY39517A
UY39517A UY0001039517A UY39517A UY39517A UY 39517 A UY39517 A UY 39517A UY 0001039517 A UY0001039517 A UY 0001039517A UY 39517 A UY39517 A UY 39517A UY 39517 A UY39517 A UY 39517A
Authority
UY
Uruguay
Prior art keywords
btk inhibitors
formula
btk
inhibitors
variables
Prior art date
Application number
UY0001039517A
Other languages
English (en)
Inventor
George Capacci Andrew
T Hopkins Brian
Bin Ma
Robin Prince
Isaac Marx
Marta Nevalainen
Martin Himmelbauer
Yin-Shiang Lin Edward
Gonzalez Lopez De Turiso Felix
Schulz Jürgen
George Vandeveer
Teyu Chen
Zain Yousaf
Vatee Pattaropong
Howard Jones John
Thomas Purgett
Simone Sciabola
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of UY39517A publication Critical patent/UY39517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I’): (I’), o sales farmacéuticamente aceptables de estos, donde las variables en la fórmula son como se definen en la presente; y métodos para su uso y producción.
UY0001039517A 2020-11-13 2021-11-12 Inhibidores de la btk UY39517A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13

Publications (1)

Publication Number Publication Date
UY39517A true UY39517A (es) 2022-06-30

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039517A UY39517A (es) 2020-11-13 2021-11-12 Inhibidores de la btk

Country Status (14)

Country Link
US (1) US20240083900A1 (es)
EP (1) EP4244223A1 (es)
JP (1) JP2023549360A (es)
KR (1) KR20230119134A (es)
CN (1) CN116783199A (es)
AR (1) AR124048A1 (es)
AU (1) AU2021377891A1 (es)
BR (1) BR112023009116A2 (es)
CL (1) CL2023001367A1 (es)
CO (1) CO2023007677A2 (es)
MX (1) MX2023005626A (es)
TW (1) TW202233624A (es)
UY (1) UY39517A (es)
WO (1) WO2022104079A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4430048A1 (en) * 2021-11-12 2024-09-18 Biogen MA Inc. Btk inhibitors
WO2023220049A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851623A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
HUE042111T2 (hu) * 2013-07-31 2019-06-28 Merck Patent Gmbh Piridinek, pirimidinek és pirazinok mint BTK inhibitorok, továbbá ezek alkalmazása
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US20220135557A1 (en) * 2018-12-07 2022-05-05 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
US20240083900A1 (en) 2024-03-14
WO2022104079A1 (en) 2022-05-19
TW202233624A (zh) 2022-09-01
CN116783199A (zh) 2023-09-19
KR20230119134A (ko) 2023-08-16
CO2023007677A2 (es) 2023-09-08
AU2021377891A9 (en) 2024-04-18
CL2023001367A1 (es) 2024-01-05
BR112023009116A2 (pt) 2023-10-03
EP4244223A1 (en) 2023-09-20
JP2023549360A (ja) 2023-11-24
AR124048A1 (es) 2023-02-08
MX2023005626A (es) 2023-07-31
AU2021377891A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
UY39517A (es) Inhibidores de la btk
UY38553A (es) Inhibidores de cdk2
CO2021009078A2 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
ECSP22033597A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
CO2022008091A2 (es) Inhibidores de kras g12c
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
UY37900A (es) Nuevos derivados de rapamicina
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
UY28695A1 (es) Derivados de difenilazetidona
UY39193A (es) Compuestos de azalactama como inhibidores de hpk1
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
UY39303A (es) Inhibidores de mutación her2
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
CL2022000147A1 (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.
UY39434A (es) Nuevos compuestos
CO2024000832A2 (es) Inhibidores de transglutaminasas